The total FDA scientific maintain formally halts all exams of Aardvark Therapeutics’ drug for Prader-Willi syndrome, a uncommon inherited metabolic dysfunction that results in extreme consuming. Earlier this yr, Aardvark voluntarily paused all exams of its small molecule after a cardiovascular downside emerged in a wholesome volunteer.
The publish Beneath FDA Scientific Maintain, Aardvark Therapeutics Seeks Path Ahead for Metabolic Drug appeared first on MedCity Information.